Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Women 65 years of age or older with epithelial ovarian cancer (EOC) are thought to have a worse prognosis than younger patients. However, no consensus exists concerning the best treatment for ovarian cancer in this age group. This report presents outcomes for patients treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Ann Surg Oncol

Title: Annals of surgical oncology

Publisher: Springer Science and Business Media LLC

ISSN (Electronic): 1534-4681

ISSN (Print): 1068-9265

Publication date (Electronic): Aug 2021

Volume: 28

Issue: 8

Affiliations

[1 ] Department of Surgical Oncology, Mercy Medical Center, The Institute for Cancer Care at Mercy, Baltimore, MD, USA.

[2 ] Department of Surgical Oncology, Mercy Medical Center, The Institute for Cancer Care at Mercy, Baltimore, MD, USA. asardi@mdmercy.com.

Article

Publisher Item ID: 10.1245/s10434-020-09415-4

DOI: 10.1245/s10434-020-09415-4

PubMed ID: 33393042

SO-VID: fb54bdc3-a141-40b7-ab75-ec85a6b6dfd5

History

Data availability:

Comments

Comment on this article

scite_

Cited by 2

See all cited by